Fitting recommendations and clinical benefit associated with use of the NAL-NL2 hearing aid prescription in Nucleus cochlear implant recipients (Record no. 2537)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02165nam a22001817a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20160506120752.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 160401b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | National Acoustic Laboratories |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | English, Ruth |
| 245 ## - TITLE STATEMENT | |
| Title | Fitting recommendations and clinical benefit associated with use of the NAL-NL2 hearing aid prescription in Nucleus cochlear implant recipients |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc | Objective: For a group of cochlear implant recipients, who use hearing aids in the contralateral ear, the benefit of NAL-NL2 relative to a<br/>recipients’ own prescription was assessed. Whether there was a preferred frequency response and/or gain deviation from NAL-NL2 was<br/>then investigated. Design: Speech recognition and self-reported ratings of benefit were examined for the recipients’ own prescription<br/>compared to the NAL-NL2 prescription, in the bimodal and hearing-aid alone conditions. Paired-comparison of hearing-aid frequency<br/>response was conducted with default NAL-NL2 and two variants, a low frequency boost or cut. Using a loudness balancing procedure, the<br/>hearing-aid gain required to achieve equal loudness between the devices was measured. Study sample: Sixteen adults with post-lingual<br/>hearing loss. Results: A 22% increase in group median word score in quiet with use of NAL-NL2 in the hearing-aid alone condition. In the<br/>bimodal condition there was no improvement with NAL-NL2. Default NAL-NL2 frequency response was preferred by 67% of participants.<br/>For 56% of participants, the preferred gain to achieve loudness balance across bimodal devices was within 5-dB of prescribed values.<br/>Conclusions: The NAL-NL2 prescription provides a high level of clinical performance, and an acceptable frequency response and gain for<br/>most participants. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cochlear implant; bimodal; acoustic hearing; hearing-aid prescription |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kerrie Plant ...[et.al.] |
| 773 0# - HOST ITEM ENTRY | |
| Relationship information | 2016; Early Online: 1–6 |
| Title | International Journal of Audiology |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/346/Fitting%20recommendations%20and%20clinical%20benefit.pdf?sequence=1&isAllowed=y">http://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/346/Fitting%20recommendations%20and%20clinical%20benefit.pdf?sequence=1&isAllowed=y</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Universal Decimal Classification |
| Koha item type | Journal article |
No items available.